Bausch Health Companies Inc. (BHC) 2003 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning. My name is Sylvia and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Valeant Pharmaceuticals International fourth quarter and the year end 2003 conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer period. (OPERATOR INSTRUCTIONS). As a reminder, this call is being recorded. At this time for opening remarks and introductions, I would like to turn the call over to Jeff Misakian, Vice President of Investor Relations. Please go ahead sir.

    早安。我叫 Sylvia,今天將擔任本次會議的主持人。此刻,我謹代表公司歡迎各位參加 Valeant Pharmaceuticals International 2003 年第四季暨全年年終電話會議。為避免任何背景雜音,所有線路均已設為靜音。在講者致詞後,將進行問答時間。(接線員指示)。提醒各位,本通話將被錄音。現在進行開場致詞與介紹,我想把電話交給投資人關係副總裁 Jeff Misakian。先生,請開始。

  • Jeff Misakian - VP of IR

    Jeff Misakian - VP of IR

  • Thank you. Good morning everyone. Welcome to Valeant's fourth quarter and year end 2003 earnings call. Before we begin, I would like to call your attention to the fact that this presentation may contain (technical difficulty) forward-looking statements that may involve risks and uncertainties including, but not limited to, projections of future sales, royalty income, operating income, returns on invested assets, regulatory approval processes, competition from generic products, marketplace and acceptance of the company's products, success of the company's strategic repositioning initiatives, and the ability of management to execute them, cost cutting measures, acceptance of the company's strategic plan and the ability to achieve financial targets and cost reduction (technical difficulty) goals and other risks detailed from time to time in Valeant's SEC filings.

    謝謝。各位早安。歡迎參加 Valeant 2003 年第四季暨全年年終財報電話會議。在開始之前,我想提醒各位,本簡報可能包含(技術問題)前瞻性陳述,可能涉及風險與不確定性,包括但不限於:未來銷售、權利金收入、營業利益、投資資產報酬、法規核准流程、學名藥競爭、市場狀況與公司產品的接受度、公司策略性重新定位措施的成功與管理階層執行能力、成本削減措施、公司策略計畫的接受度,以及達成財務目標與成本降低(技術問題)目標的能力,及其他不時於 Valeant 向 SEC 申報文件中詳述之風險。

  • These statements are based on management's current expectations and involve risks and uncertainties that include Valeant's ability to (technical difficulty) employees and reduce costs, general economic factors and business and capital market conditions, general industry trends and changes in tax law requirements and government regulation. Valeant wishes to caution the listener that these factors as well as other factors described in Valeant's SEC filings are among the factors that could cause actual results to differ materially from the expectations described in the forward looking statements.

    上述陳述係基於管理階層目前的預期,並涉及風險與不確定性,其中包括 Valeant 在(技術問題)留任員工與降低成本的能力、整體經濟因素與商業及資本市場狀況、產業整體趨勢,以及稅法要求與政府監管的變動。Valeant 提醒聽眾注意,這些因素以及 Valeant 向 SEC 申報文件中所述的其他因素,均可能導致實際結果與前瞻性陳述中所描述的預期出現重大差異。

  • Joining us on the call today are Robert W. O'Leary, Valeant's Chairman and Chief Executive Officer; Timothy C. Tyson, President and Chief Operating Officer; and Bary G. Bailey, Executive Vice President and Chief Financial Officer; Dr. Kim Lamon, President R&D and Chief Scientific Officer; Wes Wheeler, President, North America and Global Marketing and Business Development; (indiscernible), Controller; and Phil Loberg, Treasurer, are also here and available to answer questions during the Q&A session. Now I would like to turn the call over to Mr. O'Leary.

    今天與會者包括 Valeant 董事長兼執行長 Robert W. O'Leary;總裁兼營運長 Timothy C. Tyson;以及執行副總裁兼財務長 Bary G. Bailey;研發總裁兼首席科學長 Kim Lamon 博士;北美總裁暨全球行銷與業務發展總裁 Wes Wheeler;(聽不清),財務控管主管(Controller);以及財務主管(Treasurer)Phil Loberg 也在場,並將於問答時段回答問題。現在我想把電話交給 O'Leary 先生。

  • Robert W. O'Leary - Chairman and CEO

    Robert W. O'Leary - Chairman and CEO

  • Good morning everyone. Thank you for joining us today. This morning we announced another solid quarter of performance for our specialty pharmaceuticals business. We ended the year with sales improvement in nearly every region, while continuing to hold the line on expenses. This past year has been one of consistent execution of our strategic plan, a year in which we have kept our promises. Our fourth quarter and year end results reflect this execution. Our specialty pharmaceuticals business turned in a 26 percent improvement in product sales in the fourth quarter when compared to the same period a year-ago, while operating income continued to be strong. Tim Tyson will give you more detail on our core business in just a few minutes.

    各位早安。感謝各位今天加入我們。今天早上我們公布了專科藥品業務再度穩健的一季表現。我們在幾乎每個地區都以銷售成長為年度收官,同時持續嚴控費用。過去一年是我們策略計畫持續落實的一年,也是我們信守承諾的一年。第四季與全年年終的結果反映了這樣的執行力。我們的專科藥品業務在第四季的產品銷售,較去年同期成長 26%,同時營業利益仍維持強勁。Tim Tyson 將在幾分鐘後就核心業務提供更詳細的說明。

  • Royalty revenues from the sales of ribavirin continued to decline in the fourth quarter, consistent with the decrease in sales of Rebetol reported by Schering-Plough. As you know, the timing of generic competition to ribavirin in the United States continues to be an uncertainty. We are pleased that the FDA appears to be carefully reviewing the issues raised in our citizens petition filed six months ago. Nevertheless, it's important to remember that generic competition could enter the U.S. market at any time. As promised, the company makes strategic investments in the business in the fourth quarter, which impacted our cost of goods sold and research and development expenses.

    第四季來自利巴韋林(ribavirin)銷售的權利金收入持續下滑,與 Schering-Plough 所報告的 Rebetol 銷售下滑一致。如各位所知,美國利巴韋林面臨學名藥競爭的時點仍存在不確定性。我們很高興 FDA 似乎正在審慎檢視我們於六個月前提出之公民請願(citizens petition)所提出的議題。然而,重要的是要記住,學名藥競爭者可能在任何時間進入美國市場。如同承諾,公司在第四季對業務進行策略性投資,這影響了我們的銷貨成本與研發費用。

  • We kicked off our global manufacturing and supply chain initiatives in the third quarter, and our teams are well underway in executing these plans. We also initiated Phase III trials of Viramidine in the fourth quarter, and just recently told you of our plans to accelerate those trials in 2004. We continue to hold the line on overhead costs reducing our general and administrative expenses by 29 percent in the fourth quarter, compared to a year ago. All of these activities lead to an improved earnings performance in the 2003 fourth quarter compared to last year.

    我們在第三季啟動全球製造與供應鏈計畫,我們的團隊正積極推進並執行這些方案。我們也在第四季啟動 Viramidine 的第三期(Phase III)試驗,並在近期向各位說明我們計畫於 2004 年加速這些試驗。我們持續嚴控間接費用,第四季一般及行政費用較去年同期降低 29%。上述各項作為,使 2003 年第四季的獲利表現較去年有所提升。

  • Excluding the impact of the early extinguishment of debt in the fourth quarter, we reported income from continuing operations of 10.8 million or 13 cents per diluted share, a penny ahead the income from continuing operations, adjusted for nonrecurring items reported last year, and this in spite of the 63 percent decline in royalty revenue. This improvement demonstrates the magnitude of the progress we have made in our core business. I have given you the highlights of our quarterly performance. Bary Bailey will cover our detailed financial results shortly, but now I would like to turn the call over to Tim Tyson for a discussion of our business.

    若排除第四季提前清償債務(early extinguishment of debt)的影響,我們持續營業單位(continuing operations)淨利為 1,080 萬美元,或稀釋後每股 0.13 美元;較去年所報告、並就非經常性項目調整後的持續營業單位淨利高出 0.01 美元,儘管權利金收入下滑 63%。這項改善顯示我們核心業務所取得進展的幅度。以上為本季表現重點。Bary Bailey 稍後將說明更詳細的財務結果;現在我想把電話交給 Tim Tyson,請他談談我們的業務。

  • Timothy C. Tyson - President and COO

    Timothy C. Tyson - President and COO

  • Thank you, Rob, and good morning everyone. As Rob mentioned, sales were up in nearly all regions of our specialty pharmaceutical business in the fourth quarter while operating profit increased substantially over the same period last year. Once again, North America turned in solid performance with a 138 percent increase in sales to $28.2 million in the fourth quarter of 2003. In the region, operating income was $11.9 million in the fourth quarter, versus an operating loss a year ago. Our efforts to focus on our global brands continue to bear fruit.

    謝謝你,Rob,各位早安。如 Rob 所提到,我們專科藥品業務在第四季幾乎所有地區的銷售均成長,同時營業利益較去年同期大幅增加。北美再次交出穩健成績,2003 年第四季銷售成長 138%,達 2,820 萬美元。該地區第四季營業利益為 1,190 萬美元,相較於去年同期為營業損失。我們聚焦全球品牌的努力持續開花結果。

  • We experienced year-over-year increases in our core dermatology products, Efudex, Kinerase and Oxsoralen. In addition, Mestinon continued to be an important contributor in North America in the fourth quarter in spite of the generic challenge. We believe that market share declines for Mestinon in the United States have slowed and leveled off at about 50 percent according to IMS data due to the strength of this important brand. Sales in Europe were 22 percent higher in the fourth quarter totaling $62.6 million, compared to the same period last year. European sales were aided by the strength of foreign currencies in the fourth quarter which contributed $6.3 million of the sales increase over the prior-year. However, we also incurred manufacturing costs in local currencies which somewhat mitigated this impact on the operating income line.

    我們核心皮膚科產品 Efudex、Kinerase 與 Oxsoralen 的銷售均較去年同期成長。此外,儘管面臨學名藥挑戰,Mestinon 在北美第四季仍是重要的貢獻來源。我們相信,根據 IMS 數據,由於此一重要品牌的強勢,Mestinon 在美國的市占率下滑已放緩並在約 50% 左右趨於持平。歐洲第四季銷售較去年同期高出 22%,合計 6,260 萬美元。第四季外幣走強帶動歐洲銷售,較去年同期的增量中有 630 萬美元來自匯率因素。然而,我們也以當地貨幣發生製造成本,因而在營業利益項目上部分抵銷了上述影響。

  • Major product contributors to sales in the fourth quarter were Mestinon throughout Europe and Calcitonin in Spain. Dermatix, which we introduced this year, was an important contributor to the region's performance and provides an early indication of the continued success we expect to see in 2004. Operating income in Europe in the fourth quarter improved to $5 million from a loss of $1.8 million a year-ago. The issues in the European marketplace, however, have not changed with German health care reform, reference pricing legislation in Spain and Italian price controls all creating a challenging environment.

    第四季主要銷售貢獻產品包括:Mestinon(遍及歐洲)以及西班牙的 Calcitonin。我們今年推出的 Dermatix 亦為該地區表現的重要貢獻者,並初步顯示我們預期在 2004 年將持續看到的成功。歐洲第四季營業利益改善至 500 萬美元,去年同期為虧損 180 萬美元。然而,歐洲市場的議題並未改變:德國醫療改革、西班牙的參考定價立法,以及義大利的價格管制,皆使經營環境充滿挑戰。

  • In spite of these challenges, our European region has continued to perform strongly. Because of this improvement, we were able to absorb the $2.3 million in severance costs as we took initial steps to rationalize our manufacturing. In Latin America, sales were essentially flat compared to the year-ago period, while operating income declined 10 percent. The region continued to be impacted negatively by foreign currency translation which reduced sales by $1.9 million. This was partially offset by higher volume and price increases in the quarter. We have strengthened our leadership in this region by appointing Martin Mercer to oversee our operations in Latin America. Mr. Mercer's broad general management background includes market development, competitive positioning, and new product launches for pharmaceutical companies in Latin America.

    儘管面臨這些挑戰,我們的歐洲地區仍持續展現強勁表現。由於這項改善,我們在採取製造合理化的初步措施時,得以吸收 230 萬美元的資遣費用。在拉丁美洲,銷售額與去年同期相比基本持平,而營業利益下降 10%。該地區持續受到外幣換算的不利影響,使銷售額減少 190 萬美元。本季較高的銷量與價格上調部分抵銷了上述影響。我們已透過任命 Martin Mercer 負責監督拉丁美洲營運,強化我們在該地區的領導地位。Mercer 先生廣泛的綜合管理背景包括市場開發、競爭定位,以及在拉丁美洲為製藥公司推動新產品上市。

  • Prior to joining Valeant, Mr. Mercer was with GlaxoSmithKline for over 20 years holding positions of increasing responsibility in sales, marketing and general management. Mr. Mercer has extensive experience in Latin America having worked in the region for well over 25 years. His proven leadership abilities, extensive contacts in the region and knowledge of the pharmaceutical market will make a significant contribution to Valeant. Our triple-A region performed well in the fourth quarter with a 22 percent increase in sales of $13.4 million and an operating profit of $1.4 million in the quarter.

    在加入 Valeant 之前,Mercer 先生在葛蘭素史克(GlaxoSmithKline)任職超過 20 年,並在銷售、行銷與綜合管理領域擔任職責日益增加的職位。Mercer 先生在拉丁美洲擁有豐富經驗,於該地區工作已逾 25 年。他經驗證的領導能力、在該地區廣泛的人脈,以及對製藥市場的了解,將為 Valeant 帶來重大貢獻。我們的 AAA 地區在第四季表現良好,銷售額增加 22%,達 1,340 萬美元,且本季營業利益為 140 萬美元。

  • The region benefited from increased sales of Nyal, Mestinon, and Librax. Thanks to the efforts of our new leadership in the region, Reptilase (ph), a key product, contributed to fourth quarter performance. As we told you last quarter, we brought in David Kwo to strengthen our triple A region. His thirty years of experience, knowledge of the critical Asian markets and contacts have already been a tremendous asset to the company. We have focused a lot of attention on our global brand this past year through several initiatives, such as the acquisition of international rights to Kinerase, the relaunch of our Efudex solution, our Kinerase direct to consumer campaign, and our international focus on Mestinon, we have been able to grow our global products by 27 percent in 2003 to $117.8 million.

    該地區受惠於 Nyal、Mestinon 與 Librax 銷售增加。在該地區新領導團隊的努力下,Reptilase(ph)這項關鍵產品也對第四季表現有所貢獻。如同我們上季向各位提到的,我們延攬 David Kwo 以強化 AAA 地區。他三十年的經驗、對關鍵亞洲市場的了解以及人脈,已成為公司極大的資產。過去一年我們透過多項措施高度聚焦於全球品牌,例如取得 Kinerase 的國際權利、重新推出 Efudex 溶液、Kinerase 直接面向消費者的行銷活動,以及在國際市場聚焦 Mestinon,使我們在 2003 年全球產品成長 27%,達 1.178 億美元。

  • Our global products sales comprised 23 percent of total sales in 2003. On the research side of the business, our R&D teams continue to be very active and as you know have recently stepped up their pace even more. Our Phase III testing of Viramidine, which we're developing an oral form for the treatment of hepatitis C in combination with a pegylated interferon, has begun in earnest due to our accelerated initiation of the Phase III clinical trials. As a result, R&D expenses were 11 percent higher in the fourth quarter and as we previously told you, we expect the investment to increase in 2004.

    我們的全球產品銷售在 2003 年占總銷售額的 23%。在研發方面,我們的研發團隊持續非常活躍,且如各位所知,近期更進一步加快步伐。由於我們加速啟動第三期臨床試驗,我們針對 Viramidine 的第三期測試已全面展開;我們正開發其口服劑型,並與聚乙二醇化干擾素併用以治療 C 型肝炎。因此,第四季研發費用增加 11%,且如我們先前所述,我們預期 2004 年的投資將增加。

  • We're looking forward to sharing the 24 week data from Phase II studies of Viramidine at the EASL conference in Berlin in April and additional data at the DDW conference in New Orleans in May. Ribavirin (ph) which we formally refer to as Hepavire B continues to progress well. We expect to move into Phase II testing in this hepatitis B candidate in mid 2004. We're also working on a number of preclinical projects that we think show a lot of promise in the areas of HIV, hepatitis C, hepatitis B, immunology and oncology. We plan to share more with you on these projects in the near future. On the acquisition front, we recently completed our purchase of Amarin Pharmaceutical PLC's U.S. subsidiary, Amarin Pharmaceuticals, Inc. and its U.S. products. The Amarin purchase is a solid strategic fit for us which will add immediately to our revenue base while strengthening our neurology platform.

    我們期待在 4 月於柏林舉行的 EASL 會議分享 Viramidine 第二期研究的 24 週數據,並在 5 月於紐奧良舉行的 DDW 會議提供更多資料。Ribavirin(ph)(我們正式稱之為 Hepavire B)持續進展順利。我們預期於 2004 年年中,將此 B 型肝炎候選藥物推進至第二期測試。我們也正在進行多項臨床前專案,並認為其在 HIV、C 型肝炎、B 型肝炎、免疫學與腫瘤學領域展現高度潛力。我們計畫在不久的將來與各位分享更多這些專案的資訊。在併購方面,我們近期完成收購 Amarin Pharmaceutical PLC 的美國子公司 Amarin Pharmaceuticals, Inc. 及其美國產品。收購 Amarin 與我們的策略高度契合,將立即擴增我們的營收基礎,同時強化我們的神經科學平台。

  • We expect Amarin products to add nearly $20 million in annual revenues. The acquisition will be neutral to earnings in 2004, excluding the write-off of in-process R&D of approximately $10 million. In the transaction, we also obtained the rights to Zelapar, a late stage candidate for the treatment of Parkinson's disease which has an approvable letter from the FDA. We're working with Amarin to complete the safety studies required by the FDA for Zelapar this year and we hope to launch this product into the marketplace in 2005. Our business development teams are actively considering other opportunities and we hope to have more to share with you on these activities in the near future. We continue to advance several lifecycle expansion projects including our recently launched Kinerase eye cream line extension. We also have line extensions in development for Mestinon and Efudex.

    我們預期 Amarin 產品每年可增加近 2,000 萬美元營收。在不含約 1,000 萬美元在研研發(in-process R&D)沖銷的情況下,此項收購對 2004 年盈餘影響為中性。在該交易中,我們也取得 Zelapar 的權利;Zelapar 是用於治療帕金森氏症的後期候選藥物,並已收到 FDA 的可核准函(approvable letter)。我們正與 Amarin 合作於今年完成 FDA 對 Zelapar 所要求的安全性研究,並希望於 2005 年將此產品推向市場。我們的業務開發團隊正積極評估其他機會,並希望在不久的將來就這些活動與各位分享更多資訊。我們持續推進多項產品生命週期延伸專案,包括近期推出的 Kinerase 眼霜系列延伸產品。我們也正在開發 Mestinon 與 Efudex 的產品線延伸。

  • We remain confident that our specialty pharmaceuticals business can achieve industry level growth of 5 to 10 percent not including acquisitions. Turning to our operations, we began implementation of our global manufacturing and supply chain initiative in 2003, which is designed to execute our manufacturing rationalization plan. In the past year, these efforts have reduced the number of plants from 33 to 15 and the number of employees from more than 7,000 to less than 2,000 at the end of 2003. We remain confident that our manufacturing initiative will lead to cumulative cost savings of $150 to $200 million over the next five years and that it will reduce the company's manufacturing headcount to approximately 1,300 to 1,400 employees.

    我們仍有信心,在不計併購的情況下,我們的專科製藥業務可達成 5% 至 10% 的產業水準成長。談到營運方面,我們於 2003 年開始推動全球製造與供應鏈計畫,旨在執行我們的製造合理化方案。在過去一年中,這些努力已將工廠數量由 33 座降至 15 座,並將員工人數由超過 7,000 人降至 2003 年底的不足 2,000 人。我們仍有信心,製造計畫將在未來五年帶來累計 1.5 億至 2 億美元的成本節省,並將公司的製造人力降至約 1,300 至 1,400 名員工。

  • Naturally, as Rob discussed, this requires an investment in our operations, which as you saw resulted in an increase in cost of goods sold in the fourth quarter. However, these investments will pay off in the long run with a vastly more efficient network. The company's goal is to reduce inefficiencies and create a new supply network that can operate five best in class manufacturing facilities to improve our competitive position and meet our changing production requirements as our business evolves. This will reduce our cost of goods sold to between 20 and 25 percent as we have previously communicated. This effort is not just limited to our manufacturing operations.

    當然,如 Rob 所討論,這需要對我們的營運進行投資;正如各位所見,這導致第四季銷貨成本上升。然而,從長期來看,這些投資將以大幅更高效率的網路帶來回報。公司的目標是降低低效率,並建立新的供應網路,使其能以五座同級最佳(best in class)的製造設施運作,以提升我們的競爭地位,並在業務演進時滿足不斷變化的生產需求。如我們先前所傳達,這將把銷貨成本降至 20% 至 25% 之間。這項努力不僅限於我們的製造營運。

  • We have introduced the lean six sigma process to Valeant to build a passion for improving efficiencies and financial performance into the fabric of our entire operation going forward. This initiative, similar to the six sigma process at General Electric, has already been enthusiastically embraced in addition to our manufacturing operation worldwide in R&D and throughout every region of the world. We have seen significant early cost savings and expect additional benefits as we develop a positively charged company culture that is focused on efficiencies and value creation throughout every level of our organization. We will have more to report on this in the future. Now, I will turn the call over to Bary Bailey.

    我們已將精實六標準差(Lean Six Sigma)流程導入 Valeant,使提升效率與財務績效的熱忱成為未來整體營運文化的一部分。此項倡議類似於通用電氣(General Electric)的六標準差流程,除全球製造營運外,也已在研發以及全球各地區獲得熱烈採納。我們已看到顯著的早期成本節省,並預期隨著我們培養一種積極正向、聚焦於效率與價值創造的公司文化,將在組織各層級帶來更多效益。未來我們將就此提供更多報告。現在,我將把電話會議交給 Bary Bailey。

  • Bary G. Bailey - EVP and CFO

    Bary G. Bailey - EVP and CFO

  • Thank you Tim. As Tim has already discussed, our topline sales results for the fourth quarter were quite strong with an increase of $29.8 million or a 26 percent increase over the prior-year. Excluding the impact of foreign currency products sales were still up 20 percent over last year. Royalty revenues declined 63 percent in the fourth quarter to $30.7 million reflecting lower Rebetol sales by Schering-Plough due to their continued inventory reduction challenges which were exacerbated by the competitive challenges from Roche to their hepatitis C franchise.

    謝謝你,Tim。如 Tim 已經討論過的,我們第四季的營收(topline)表現相當強勁,較去年同期增加 2,980 萬美元,增幅為 26%。若排除外幣影響,產品銷售額仍較去年成長 20%。第四季權利金收入下降 63% 至 3,070 萬美元,反映出 Schering-Plough 的 Rebetol 銷售下滑;其原因在於其持續面臨庫存去化的挑戰,而羅氏(Roche)對其 C 型肝炎產品線的競爭壓力亦使情況惡化。

  • We also receive royalties from Roche on sales of Copegus but at a lower rate than that paid by Schering. Approximately three quarters of the total royalties in the fourth quarter were from sales of oral ribavirin outside the U.S. As Rob mentioned, we continue to expect generic competition in the critical U.S. market soon but cannot predict when that may occur. Thus it is difficult to predict the level of royalty revenues we will receive in 2004. Our gross margin increased to 63 percent in the fourth quarter from 62 percent in the same period last year.

    我們也從羅氏(Roche)就 Copegus 的銷售收取權利金,但費率低於 Schering 所支付的費率。第四季權利金總額中,約四分之三來自美國以外地區口服利巴韋林(ribavirin)的銷售。如 Rob 所提到的,我們仍預期關鍵的美國市場不久將出現學名藥競爭,但無法預測何時會發生。因此,很難預測我們在 2004 年將收到的權利金收入水準。我們的毛利率在第四季由去年同期的 62% 提升至 63%。

  • The increase was primarily due to a combined change in product and geographic mix with more sales of high margin products and increased contributions from North America. The margin is somewhat lower than in the third quarter reflecting the timing of certain efforts related to our manufacturing rationalization. As Tim mentioned, we continue to make investments in our operations to drive efficiencies which increased cost of goods sold. Specifically we incurred $2.3 million in severance costs in the planned divestiture of our manufacturing facility in Spain and accelerated depreciation expense of $1.6 million in the fourth quarter.

    此增幅主要是由產品與地理組合的綜合變化所致,高毛利產品銷售增加,且北美地區的貢獻提升。毛利率較第三季略低,反映了與製造整併(rationalization)相關之特定工作在時點上的影響。如 Tim 所提到的,我們持續投資營運以提升效率,這使銷貨成本增加。具體而言,我們在計畫出售西班牙製造廠的過程中產生了 230 萬美元的資遣費用,並於第四季認列 160 萬美元的加速折舊費用。

  • We expect accelerated depreciation associated with the global manufacturing initiative to add $6.4 million in incremental expense in 2004. In spite of this investment, we continue to expect our gross margin in 2004 to be in the range of 64 to 66 percent. Selling expenses were only marginally higher on an absolute basis in the fourth quarter, in spite of the 26 percent increase in product sales. General and administrative expenses were down almost 30 percent in the fourth quarter compared to a year ago reflecting our continued efforts to keep costs under control, especially in the areas of legal and consulting expenses.

    我們預期與全球製造計畫相關的加速折舊,將在 2004 年增加 640 萬美元的額外費用。儘管有此投資,我們仍預期 2004 年毛利率將落在 64% 至 66% 的區間。第四季銷售費用以絕對金額計僅小幅增加,儘管產品銷售成長了 26%。一般及行政費用(G&A)在第四季較去年同期下降近 30%,反映我們持續努力控制成本,尤其是在法律與顧問費用方面。

  • Selling expenses declined to 32 percent of sales of the fourth quarter compared to 39 percent in the same period last year while G&A expense declined to 18 percent compared to 33 percent last year. Overall, SG&A was 51 percent of sales in the fourth quarter compared to 71 percent a year ago. These are significant improvements in our key metrics. The reduction in G&A in the fourth quarter reflects our continued effort to hold overhead down. But, on a prospective basis, we continue to anticipate G&A expense for 2004 in the range of 20 to 21 percent of sales.

    第四季銷售費用占銷售額比重降至 32%,去年同期為 39%;而一般及行政費用占比降至 18%,去年為 33%。整體而言,第四季銷售、一般及行政費用(SG&A)占銷售額比重為 51%,去年同期為 71%。這些都是我們關鍵指標上的重大改善。第四季 G&A 的下降反映我們持續努力壓低間接費用。但從前瞻角度來看,我們仍預期 2004 年 G&A 費用將約占銷售額的 20% 至 21%。

  • Now with respect to selling expenses, we expect to see early investments in 2004, with selling and advertising expenses be higher in the first half of the year as a percentage of sales than in the last half of the year. However, we continue to be confident with our previous communications for the full year 2004 at between 30 and 32 percent. Amortization expense was 73 percent higher in the fourth quarter due principally to the increased amortization from the Ribapharm acquisition as we previously disclosed. We expect to see additional amortization expense from our recent acquisition of Amarin and are currently looking at amortization expense in 2004 to be in the range of $50 to $55 million.

    至於銷售費用方面,我們預期 2004 年將出現前期投資,銷售與廣告費用在上半年占銷售額的比重將高於下半年。然而,就 2004 全年而言,我們仍對先前對外溝通的 30% 至 32% 區間保持信心。第四季攤銷費用增加 73%,主要是由於我們先前揭露的 Ribapharm 收購案帶來攤銷增加。我們預期近期收購 Amarin 也將帶來額外攤銷費用,目前估計 2004 年攤銷費用將落在 5,000 萬至 5,500 萬美元。

  • The company's effective tax rate for continuing operations in the fourth quarter and for the year was 38 percent. We continue to expect an effective rate in 2004 of between 36 and 37 percent. As you know, we took steps in the fourth quarter to restructure our debt obligation adding two tranches of convertible subordinated notes with $240 million principal amount in each tranche, along with $300 million in Senior Notes. In total we issued $780 million in new debt in the quarter. The notes provide us with a better maturity structure, lower our overall interest rates and provide us with cash for potential acquisitions.

    公司第四季及全年持續營運的有效稅率為 38%。我們仍預期 2004 年有效稅率介於 36% 至 37%。如各位所知,我們在第四季採取措施重整債務義務,新增兩個批次的可轉換次順位公司債,每一批次本金各為 2.4 億美元,並同時發行 3 億美元的優先票據(Senior Notes)。本季合計發行 7.8 億美元的新債務。這些票據使我們的到期結構更佳、降低整體利率,並為潛在收購提供現金。

  • We repurchased $140 million of Valeant's existing 6.5 percent convertible notes in the fourth quarter at a pre-tax loss of $12.8 million. As previously disclosed, we intend to purchase the remaining $326 million of the 6.5 percent convertible notes on or prior to the first redemption date in July of 2004. Based on the July date redemption price of 103.7, this would result in a pre-tax loss of $19 million in 2004. In January 2004, the company entered into an interest rate swap agreement on 150 million of Valeant's new Senior Notes to (indiscernible) our effective rate interest rate on these instruments.

    我們在第四季以稅前 1,280 萬美元的損失,回購了 1.4 億美元 Valeant 既有的 6.5% 可轉換公司債。如先前揭露,我們擬於 2004 年 7 月的首次贖回日當日或之前,買回剩餘 3.26 億美元的 6.5% 可轉換公司債。以 7 月贖回價格 103.7 計算,這將在 2004 年造成 1,900 萬美元的稅前損失。2004 年 1 月,公司就 Valeant 新發行的 1.5 億美元優先票據簽訂利率交換協議,以(聽不清)我們在這些工具上的有效利率。

  • We exchanged fixed-rate interest payments at 7 percent for a floating-rate payment at 2.409 percent over LIBOR resulting in a current rate of approximately 3.6 percent. Overall, we expect net interest expense in 2004 to be approximately $40 million assuming a July 2004 redemption of a 6.5 percent convertible note. We ended the year with a total long-term debt balance of $1.1 billion, a significant increase over the $482 million at the end of 2002. Our cash at December 31, 2003, was significantly higher as well totaling $872 million. Excluding potential acquisitions, we expect cash to be in the range of $500 to $550 million after the redemption or repurchase of the remaining 6.5 percent convertible note.

    我們將 7% 的固定利率利息支付,交換為以 LIBOR 加 2.409% 計算的浮動利率支付,使目前利率約為 3.6%。整體而言,假設於 2004 年 7 月贖回 6.5% 可轉換公司債,我們預期 2004 年淨利息費用約為 4,000 萬美元。年底時,我們的長期負債總額為 11 億美元,較 2002 年底的 4.82 億美元大幅增加。截至 2003 年 12 月 31 日,我們的現金也顯著提高,合計 8.72 億美元。在不考慮潛在收購的情況下,我們預期在贖回或回購剩餘 6.5% 可轉換公司債後,現金將落在 5 億至 5.5 億美元的區間。

  • Discontinued operations at December 31, reflect the company's API business in Chek and Hungary with a total -- net book value of approximately $10 million. We continue to actively market this business and expect to complete this sale this year. The loss from discontinued operations in the fourth quarter was due to losses from operation in the quarter. The loss in 2002 was primarily due to a write-down of the discontinued operations. Now, I would like turn it back over to Rob for closing comments.

    截至 12 月 31 日的停業部門,反映公司位於捷克與匈牙利的 API(原料藥)業務,其合計淨帳面價值約為 1,000 萬美元。我們持續積極推銷該業務,並預期今年完成出售。第四季停業部門的損失係由本季營運虧損所致。2002 年的損失主要是因停業部門的減記。現在,我想把時間交回給 Rob 作結語。

  • Robert W. O'Leary - Chairman and CEO

    Robert W. O'Leary - Chairman and CEO

  • Thank you Bary. As we have said before, 2004 will be a year of investment in the business as we drive efficiencies in our manufacturing operations and accelerate our research and development activities. We remain confident that that we will manage within the metrics that we have previously disclosed for 2004, and that we will achieve the 2008 target that we presented in September in our strategic plan. Let me ask you now to take a moment and pause and reflect with me on what has been a truly amazing 12 months for the company we now call Valeant. The company this management team inherited in 2002 was complex and unfocused and with very little transparency. It was centered on Eastern Europe and Russia, in numerous unrelated and for the most part unprofitable businesses, with an unnatural emphasis on topline growth at the expense of earnings and an over dependence on royalties.

    謝謝你,Bary。如我們先前所說,2004 年將是對業務進行投資的一年,我們將提升製造營運效率並加速研發活動。我們仍有信心能在先前揭露的 2004 年各項指標範圍內進行管理,並達成我們在 9 月於策略計畫中提出的 2008 年目標。現在請各位花一點時間,與我一起停下來回顧:對我們如今稱為 Valeant 的公司而言,這確實是令人驚嘆的 12 個月。這個管理團隊在 2002 年接手的公司結構複雜、缺乏聚焦,且透明度極低。其重心在東歐與俄羅斯,涉足眾多彼此無關且多數不獲利的業務,並以犧牲獲利為代價不自然地強調營收成長,且過度依賴權利金。

  • The company, the company's management team and board were more focused on self-fulfillment rather than shareholder value creation and as ludicrous as it sounds, for a pharmaceutical organization, the company had little or no control or influence over its own research and development capabilities. In marked contrast, Valeant today as a result of our highly successful divestment program is a far less complex and more transparent company that is devoid of unrelated businesses and focused solely on specialty pharma, nine global products in ten key markets.

    公司、公司的管理團隊與董事會更著重於自我滿足,而非為股東創造價值;而且儘管聽起來荒謬,作為一家製藥組織,公司對自身的研發能力幾乎沒有任何控制或影響力。形成鮮明對比的是,今日的 Valeant 由於我們極為成功的資產剝離計畫,已成為一家複雜度大幅降低且更透明的公司,剔除無關業務,專注於專科製藥,在十個關鍵市場擁有九項全球產品。

  • The former ICN bloated and inefficient manufacturing capability has been dramatically rationalized from 33 plants to 15 with more to come. Valeant today has only 42 percent of the employee headcount we had just one year ago. Our balance sheet has been dramatically upgraded. We have spread out our maturities and now we have some real acquisition muscle. The new management team which has been built in record time I regard as potentially be best in this industry and there has been a substantive and complete change in our governance profile. What was before an embarrassment is increasingly being recognized as a model of best practices in this new governance environment, but it is in research and development where there has been the most dramatic transformation.

    先前 ICN 臃腫且效率低落的製造能力已大幅合理化,工廠數量由 33 座縮減至 15 座,後續仍將進一步縮減。Valeant 目前的員工人數僅為一年前的 42%。我們的資產負債表已大幅改善。我們已分散到期結構,現在也具備真正的併購實力。這支在創紀錄時間內建立的新管理團隊,我認為有潛力成為本產業最佳之一,而我們的公司治理樣貌也已發生實質且全面的改變。過去令人尷尬的情況,如今在新的治理環境下愈來愈被視為最佳實務的典範;但最劇烈的轉型其實發生在研發領域。

  • We have competent new leadership and have built significantly on our great scientific drug discovery and preclinical development capabilities with the addition of expertise in clinical, regulatory, biometrics and project management, competent people have all done it before and have been immensely successful. This has resulted in our unprecedented early entry into Phase III in Viramidine and management's unbridled enthusiasm for increased and accelerated investments in our research and development capability. The bottom line on all of this is that Valeant today has a significantly different strategic platform upon which to grow the company and dramatically increase shareholder value. I want to thank you for your time and we will be pleased to take your questions at this time.

    我們擁有稱職的新領導團隊,並在既有優秀的科學藥物發現與臨床前開發能力上大幅強化,新增了臨床、法規、生物統計與專案管理等專業;這些稱職的人才都曾有相關經驗且極為成功。這使我們在 Viramidine 上以前所未有的速度提前進入第三期臨床試驗,也讓管理階層對於加大並加速投資研發能力充滿熱情。總結而言,Valeant 今日已具備顯著不同的策略平台,可據以成長並大幅提升股東價值。感謝各位撥冗,我們現在很樂意回答各位的問題。

  • Operator

    Operator

  • (OPERATOR INSTRUCTIONS). Michael Tong with Wachovia Securities.

    (接線員指示)。Wachovia Securities 的 Michael Tong。

  • Michael Tong - Analyst

    Michael Tong - Analyst

  • Good morning. Just a couple of quick questions. Number one is, could you give us an idea of in the Phase III for Viramidine how many patients have been enrolled and how many are actually on treatment right now? Bary, I might have missed this when you said the gross margin expectation for '04 of 64 to 66 percent. Does that include or exclude the accelerated depreciation?

    早安。我有幾個簡短問題。第一,Viramidine 的第三期臨床試驗目前大約已納入多少名病患?現在實際正在接受治療的有多少人?Bary,你提到 2004 年毛利率預期為 64% 到 66%,我可能漏聽了。這個數字是否包含或排除加速折舊?

  • Unidentified Company Representative

    Unidentified Company Representative

  • Bary is going to answer that question first and then Dr. Lamon will take the Viramidine question.

    Bary 會先回答那個問題,接著 Lamon 醫師會回答 Viramidine 的問題。

  • Bary G. Bailey - EVP and CFO

    Bary G. Bailey - EVP and CFO

  • That includes the accelerated appreciation.

    這包含加速折舊。

  • Dr. Kim D. Lamon - President R&D and Chief Scientific Officer

    Dr. Kim D. Lamon - President R&D and Chief Scientific Officer

  • I want to let you know that the Phase III program that we started is going very, very well and we are very happy with the progress, but it is still early. We're still in the ramp-up phase, but we are very happy with what has occurred over the last couple of months.

    我想讓各位知道,我們啟動的第三期計畫進展非常、非常順利,我們對進度非常滿意,但目前仍屬早期階段。我們仍在爬坡期,但對過去幾個月的進展非常滿意。

  • Michael Tong - Analyst

    Michael Tong - Analyst

  • Great. Thank you. I will jump back into queue.

    很好。謝謝。我回到等候隊列。

  • Operator

    Operator

  • Robert Uhl with Wells Fargo Securities.

    Wells Fargo Securities 的 Robert Uhl。

  • Robert Uhl - Analyst

    Robert Uhl - Analyst

  • Thank you. Can you just go over some of the specific programs you have put in place to revitalize if you call it the U.S. business. Which products are you focusing on, what are the salespeople out selling? What is the marketing thrust at this point?

    謝謝。你能否再說明一下你們為振興(如果你們稱之為)美國業務所採取的一些具體方案?你們聚焦哪些產品?業務人員主要在銷售什麼?目前的行銷主軸是什麼?

  • Timothy C. Tyson - President and COO

    Timothy C. Tyson - President and COO

  • As we have indicated, we're focusing on the core areas of our business and in the United States we're focusing on dermatology, and we have focused on Kinerase, Efudex, and Glyquin. We also have had some activity around Mestinon to ensure that we are able to retain as much business as possible. There has been significant activity by Wes Wheeler to restructure the salesforce, provide new marketing tools and messages, talk about the direct to consumer advertisement campaign on Kinerase; basically a whole revitalization of the focus for targeting for the salesforce and for new marketing tools for our U.S. operation. I want to also remind you that we have focused on and resolved early the inventory issues that existed in the U.S. business.

    如我們所指出的,我們正聚焦於業務的核心領域;在美國方面,我們聚焦皮膚科,並著重於 Kinerase、Efudex 與 Glyquin。我們也針對 Mestinon 採取了一些行動,以確保能盡可能保留業務量。Wes Wheeler 已進行大量工作來重整銷售團隊、提供新的行銷工具與訊息,並推動 Kinerase 的消費者直效(DTC)廣告活動;基本上就是全面振興我們美國營運的銷售團隊目標設定與新的行銷工具。我也想提醒各位,我們已優先聚焦並及早解決美國業務原先存在的庫存問題。

  • Robert Uhl - Analyst

    Robert Uhl - Analyst

  • If one looks at IMS data, all of those products you named are still highly negative prescription results when you look at year-over-year comparisons. So, at some point that should turn. Why haven't we seen evidence of that yet?

    如果看 IMS 的數據,你剛提到的那些產品在年度同比比較下,處方表現仍然大幅為負。所以,某個時間點應該會反轉。為什麼我們還沒看到相關證據?

  • Wes Wheeler - President, North America and Global Marketing and Business Development

    Wes Wheeler - President, North America and Global Marketing and Business Development

  • In terms of Efudex, we have actually grown the IMS market share from about 49 percent a year ago to, we're currently holding about 52 percent of that market. The market is more or less mature, it is growing slightly. But our market share has actually grown year on year for Efudex. On Mestinon, the reason why the market share has gone down and the volume has gone down is because we've had three generics enter the market in the last 12 months and we have actually held onto a major part of that business because of our patient loyalty.

    就 Efudex 而言,我們的 IMS 市占率已從一年前約 49% 成長到目前約 52%。該市場大致成熟,僅略有成長。但 Efudex 的市占率確實已逐年提升。至於 Mestinon,市占與銷量下滑的原因是過去 12 個月有三個學名藥進入市場;但由於病患忠誠度,我們實際上仍保住了該業務的主要部分。

  • Robert Uhl - Analyst

    Robert Uhl - Analyst

  • I guess I'm looking at prescriptions and not share. So prescriptions are down 19 percent in January for the company overall. That is barely an improvement from the 25 percent decline that was reported a year ago.

    我想我看的是處方量而不是市占。所以公司整體 1 月處方量下滑 19%。這相較於一年前報告的 25% 下滑,幾乎沒有改善。

  • Unidentified Company Representative

    Unidentified Company Representative

  • We're not sure what date you're looking at, Michael, but what Wes indicated to you is the facts that we have and of course you can see the financial performance Robert of the market place. So, I think that any detailed information on market share or prescription data we would be glad to talk with you, but we don't have all of the data in front of us. But, we're very confident of the performance and our focus in the U.S. marketplace.

    Michael,我們不確定你看的日期是哪一天;但 Wes 向你說明的是我們掌握的事實,當然你也能從市場表現看到財務結果,Robert。因此,若要更細部的市占或處方數據,我們很樂意再與你討論,但我們目前手邊沒有完整數據。不過,我們對美國市場的表現與我們的聚焦方向非常有信心。

  • Operator

    Operator

  • Michael Stansky (ph) from Tutor Investments.

    Tutor Investments 的 Michael Stansky(音)。

  • Michael Stansky - Analyst

    Michael Stansky - Analyst

  • Tim, you talked about an accelerated manufacturing spend that impacted gross margins in the fourth quarter. Bary gave us severance and accelerated depreciation impact. Can you tell us roughly how much that hit the gross margins in the fourth quarter and more importantly how you see that unwinding or impacting '04?

    Tim,你提到第四季有加速的製造支出影響了毛利率。Bary 提供了資遣費與加速折舊的影響。你能否大致說明第四季毛利率因此受到多大衝擊?更重要的是,你如何看待這在 2004 年的回轉或影響?

  • Timothy C. Tyson - President and COO

    Timothy C. Tyson - President and COO

  • I will give you a couple of comments and Bary can talk about how it impacts directly gross margins in the fourth quarter. But we are in the middle of detailed implementation just as we have indicated. There are a lot of moving parts and the manufacturing costs have come down from the information, and as this management has begun the responsibility back in mid 2002, from a 41.5 percent to the end of the year at 36 percent. There are going to be some quarterly fluctuations, but right now we have some significant activity going on to reduce the number of people and to move products from sites that we have to sites that we are going to keep.

    我先補充幾點,接著 Bary 可以談談它對第四季毛利率的直接影響。但如我們所述,我們正處於細部落實的中期。其中有許多變動因素;根據相關資訊,自本管理團隊於 2002 年年中開始承擔責任以來,製造成本已由 41.5% 降至年底的 36%。季度之間會有一些波動,但目前我們正積極推動減少人力,並將產品從現有據點移轉至我們將保留的據點。

  • All of that is taking investment to prepare ourselves by writing regulatory dossiers so that we can submit them to regulatory authorities so that we are able to affect the move to reduce the number of sites that we have by selling them off to get to the five sites that we have discussed. So, that is what is going on, that is what you're seeing, and all of these are part of an aggressive implementation of our manufacturing master plan.

    所有這些都需要投入資金來做準備,例如撰寫法規申報資料(regulatory dossiers),以便提交給主管機關,讓我們能推動移轉並透過出售據點來減少現有廠址數量,最終達到我們所討論的五個據點。所以,這就是目前正在發生的事,也是你所看到的情況;而這些都是我們積極推動製造總體計畫(manufacturing master plan)的一部分。

  • Bary G. Bailey - EVP and CFO

    Bary G. Bailey - EVP and CFO

  • The amounts that we have specifically identified though as events if you will are the accelerated depreciation which we have communicated, and we have moved up on the severance by reduction in force in Spain predominately. We are starting to take those steps to move that process along and those are the only two items that we see as, if you will, almost specific in nature.

    不過,我們明確辨識、可視為事件的金額主要是我們已對外溝通的加速折舊,以及主要發生在西班牙、因裁員(reduction in force)而提前認列的資遣費。我們正開始採取這些步驟以推進流程;而我們目前看到、可說幾乎屬於特定性質的項目就只有這兩項。

  • Robert W. O'Leary - Chairman and CEO

    Robert W. O'Leary - Chairman and CEO

  • To sort of give you a high-level overview, I'm sure you sense it, but just to remind everyone that within what we call the manufacturing rationalization plan there are actually too -- many things going on but two major thrusts. One, the efforts to do everything we need to do to move from approximately ten plus plants into a concentrated five plants, so that involves as Tim said, new dossiers and all of that stuff. But at the same time and in parallel, we are making major efforts through our lean six sigma program to dramatically improve the operations throughout the manufacturing environment.

    為了給各位一個高層次的概覽,我相信你們也感受得到,但還是提醒大家,在我們所稱的製造合理化計畫之中,實際上有太多——很多事情同時在進行,但有兩個主要推進方向。第一,是我們努力完成所有必要工作,將大約十多座工廠整併為集中化的五座工廠,因此如 Tim 所說,這涉及新的申報資料(dossiers)以及所有相關事項。但同時、並行地,我們也透過精實六標準差(Lean Six Sigma)計畫在整個製造環境中大幅改善營運。

  • That of course requires investment in education, training. We've now got an impressive number of what they called black belts and green belts in the lean six sigma program and people have been taking off the line, some of our best people, and then put through this intensive training so that we can come -- what we want to do is come out of this with not just a reduction to five plants, but a reduction to five highly efficient plants and that is requiring the additional investment as we move through these early stages of the manufacturing plan.

    這當然需要在教育與訓練上的投資。我們現在在精實六標準差計畫中擁有相當可觀數量的所謂黑帶與綠帶;我們讓一些最優秀的人才暫時離開產線,接受這種密集訓練,目標是——我們希望最終不只是把工廠數量減到五座,而是減到五座高度效率的工廠;而在製造計畫的早期階段推進時,這需要額外投資。

  • Michael Stansky - Analyst

    Michael Stansky - Analyst

  • That should be something that basically takes place through all of '04?

    這基本上會在整個 2004 年完成嗎?

  • Robert W. O'Leary - Chairman and CEO

    Robert W. O'Leary - Chairman and CEO

  • Actually it takes place through all of '04 and '05 but the benefits, the cost investment is particularly in the lean six sigma activities, is primarily on the front end and the benefits of course will start to be realized in 2005 and beyond. But there is a bubble here, somewhat of a bubble at the beginning on the investment and while we wait to have some of this flow through to the improvements we expect.

    其實會貫穿 2004 年與 2005 年,但效益方面——成本投入特別是在精實六標準差活動上——主要集中在前期;而效益當然會從 2005 年及之後開始逐步顯現。不過在一開始投資會有一個「隆起」——某種程度上的高峰——在我們等待這些投入轉化為預期改善的期間。

  • Michael Stansky - Analyst

    Michael Stansky - Analyst

  • One other quick question, if Kim is on. You mentioned an internal pipeline of HIV, hep C and hep B. Is there anything close enough to discuss those products, those efforts?

    另外一個很快的問題,如果 Kim 在線的話。你提到 HIV、丙肝(hep C)與乙肝(hep B)的內部研發管線。這些產品或相關工作有沒有任何進展到足以討論的程度?

  • Dr. Kim D. Lamon - President R&D and Chief Scientific Officer

    Dr. Kim D. Lamon - President R&D and Chief Scientific Officer

  • I think those are really a bit early to comment on. You may know that we have both nucleoside and non-nucleoside libraries, so each of those programs if you will, is duplicated. So an HIV in both nucleoside and non-nucleoside, it is really too early to communicate more than that to you.

    我認為那些目前還稍早,還不太適合評論。你可能知道我們同時有核苷類(nucleoside)與非核苷類(non-nucleoside)的化合物庫,因此每一個計畫(如果你願意這麼說)都是成對並行的。所以 HIV 在核苷類與非核苷類兩邊都有,但目前真的還太早,無法向你傳達更多細節。

  • Michael Stansky - Analyst

    Michael Stansky - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Todd Krasear (ph) with Bear Stearns.

    Bear Stearns 的 Todd Krasear(音)。

  • Todd Krasear - Analyst

    Todd Krasear - Analyst

  • I was just wondering if on the gross margin front, just a little more color on what you're doing in terms of the supply chain initiatives? And then if you could also just indicate that given the severance costs that were there in the fourth quarter and it sounds like are expected to continue on through 2004, that is all baked into your expectations of a 64 percent to 66 percent gross margin?

    我想請教一下毛利率方面,能否多補充一些你們在供應鏈倡議(supply chain initiatives)上所做的事情?另外,你是否也能說明:考量第四季已發生的資遣成本(severance costs),而且聽起來 2004 年仍預期會持續,這些是否都已納入你們對 64% 到 66% 毛利率的預期之中?

  • Bary G. Bailey - EVP and CFO

    Bary G. Bailey - EVP and CFO

  • It is absolutely baked into our expectations that we have communicated.

    這絕對已經納入我們對外溝通的預期之中。

  • Todd Krasear - Analyst

    Todd Krasear - Analyst

  • You were at the bottom, I guess the bottom. If you exclude -- well I guess excluding this severance expense you would've been at about 64 percent but you think with the severance expense in there, you could still be at 64 percent or better in 2004?

    你們當時在底部,我想是底部。如果排除——嗯,我想若排除這筆資遣費用,你們大概會在 64% 左右;但你們認為把資遣費用算進去,2004 年仍能達到 64% 或更高嗎?

  • Bary G. Bailey - EVP and CFO

    Bary G. Bailey - EVP and CFO

  • We have expected in all of our cases, we're looking and we see opportunities for selling the facilities with the majority of the employees in place. What we have done is we have looked at the staffing levels in the facilities and saw opportunities for efficiencies that frankly the buying parties would not want to pick up anyway. So we have addressed that upfront and tried to resolve it in advance. We don't see a substantial amount of that on a prospective basis.

    在我們所有的情境假設中,我們都在觀察並看到機會:出售這些設施時,讓大多數員工仍留在原地。我們已檢視各設施的人力配置水準,並看到一些效率提升的機會;坦白說,買方也不會想承接那些人力。因此我們已在前端先行處理,並嘗試提前解決。從前瞻角度來看,我們不認為這部分會有很大的量。

  • Todd Krasear - Analyst

    Todd Krasear - Analyst

  • But in terms of the severance expense, you don't anticipate say in the first half of '04 that you might continue to be below your guidance range for the year?

    但就資遣費用而言,你們不預期例如在 2004 年上半年,可能會持續低於你們對全年所給的指引區間嗎?

  • Unidentified Company Representative

    Unidentified Company Representative

  • We will meet the guidance range by the end of the year. We have some significant investments going on in the early part of the year that will effect the gross margin or cost of goods sold. So yes, we do expect it to continue. It probably will not be based on letting people go or severance costs because as Bary said we expect to sell the facilities that we have with the majority of the people in the facilities.

    我們會在年底達成指引區間。年初我們有一些重大投資正在進行,會影響毛利率或銷貨成本(cost of goods sold)。所以是的,我們確實預期這種影響會持續。但它可能不會是因為裁員或資遣成本,因為如 Bary 所說,我們預期出售我們的設施時,設施內的大多數人員會一併留任。

  • Todd Krasear - Analyst

    Todd Krasear - Analyst

  • Could you on the supply chain initiatives, could you just give a little more color around what you are doing there?

    關於供應鏈倡議,你能否再多補充一些你們具體在做什麼?

  • Bary G. Bailey - EVP and CFO

    Bary G. Bailey - EVP and CFO

  • Certainly. The supply chain initiative is focused on a few things. Most of the cost and manufacturing come from headcount and from the number of sites that we have. As we have communicated, we have a plan to go from 33 sites to 5 sites, to take the headcount from more than 7,000 to around 1,300 to 1,400, and to reduce the cost of goods from 20 to 25 percent. That includes the manufacturing rationalization that I just discussed, it also includes some implementation in benefit from lean six sigma as Rob had indicated, it also includes the application of global procurement activities so that we will gain some benefit from our global buying power.

    當然可以。供應鏈倡議聚焦在幾個面向。製造成本的大部分來自人力編制(headcount)以及我們擁有的據點數量。如我們已對外溝通,我們的計畫是把據點從 33 個降到 5 個,把人力從 7,000 多人降到約 1,300 到 1,400 人,並將銷貨成本降低 20% 到 25%。這包含我剛才談到的製造合理化,也包含如 Rob 所指出的精實六標準差的導入與效益,還包含全球採購活動的運用,讓我們能從全球採購規模(global buying power)中獲得一些效益。

  • Todd Krasear - Analyst

    Todd Krasear - Analyst

  • Great. One other thing then I'll get back in queue. In terms of selling expense, could you repeat what you said the guidance would be for '04? Is it 30 to 32 or did you say it was 32 to 33?

    很好。另外一件事,然後我就回到排隊等候。就銷售費用(selling expense)而言,你能重複一下你們對 2004 年的指引是什麼嗎?是 30 到 32,還是你說的是 32 到 33?

  • Bary G. Bailey - EVP and CFO

    Bary G. Bailey - EVP and CFO

  • We said 30 to 32.

    我們說的是 30 到 32。

  • Todd Krasear - Analyst

    Todd Krasear - Analyst

  • Okay. Thanks very much. I will get back into queue.

    好的。非常感謝。我回到排隊等候。

  • Operator

    Operator

  • Diana Monteith (ph) from Loomis Sayles.

    Loomis Sayles 的 Diana Monteith(音)。

  • Diana Monteith - Analyst

    Diana Monteith - Analyst

  • My questions have been answered.

    我的問題都已經被回答了。

  • Operator

    Operator

  • Dave Groober with Meisenbach Capital.

    Meisenbach Capital 的 Dave Groober。

  • Dave Groober - Analyst

    Dave Groober - Analyst

  • Royalties declined 21 percent in the second quarter, 43 in the third and now 63 percent. Phar (ph) Pharmaceuticals has received an approvable letter for ribavirin. So assuming shared exclusivity, what are your expectations for ribavirin royalties in '04 given the accelerated mix change between Schering and Roche and the pending launch of a generic ribavirin, and if you could use '03 royalties of 168 million (technical difficulty)? Could you help us out there please?

    權利金在第二季下滑 21%,第三季下滑 43%,而現在下滑 63%。Phar(音)製藥已收到 ribavirin 的可核准函(approvable letter)。因此在假設共享獨占(shared exclusivity)的情況下,考量 Schering 與 Roche 之間加速的產品組合轉移,以及學名藥 ribavirin 即將上市,你們對 2004 年 ribavirin 權利金的預期是什麼?如果可以用 2003 年 1.68 億美元的權利金作為基準(技術問題)——能否請你們協助說明一下?

  • Unidentified Company Representative

    Unidentified Company Representative

  • The impact that we have on royalties is affected by many things. Firstly, it will be affected as a generic comes into the marketplace, but as you know there has not been a generic in the marketplace. It's affected mostly by two things. Number one the competition, and the market share between Schering and Roche, and also by the fact that there was some significant inventory that Schering had. So those dynamics are what have affected our royalty revenues and you have heard some of those things as you have heard both Roche and Schering's discussion on earnings.

    我們的權利金所受影響取決於很多因素。首先,當學名藥進入市場時會受到影響,但如你所知,目前市場上尚未出現學名藥。它主要受兩件事影響。第一是競爭,以及 Schering 與 Roche 之間的市占率變化;第二是 Schering 先前有一些相當可觀的庫存。因此,這些動態因素影響了我們的權利金收入;你也在 Roche 與 Schering 的財報討論中聽到過其中一些內容。

  • Dave Groober - Analyst

    Dave Groober - Analyst

  • Can we make an assumption -- I guess maybe premature. How does the decline in the ribavirin loyalties affect profitability? If you back out the royalty number to some degree, the base business profitability is minimal, even a loss in that regard. Could you walk us through that? I am just trying to better understand. There are lots of investments that have to be had, at the same time your key driver will be cut next year or this year?

    我們能否做個假設——我想也許還太早。ribavirin 權利金下滑對獲利能力有何影響?如果把權利金數字在某種程度上扣除,你們的基礎業務獲利能力其實很有限,甚至在那個角度看是虧損。你能帶我們走一遍這個邏輯嗎?我只是想更清楚理解。有很多投資必須進行,同時你們的關鍵驅動因素明年或今年會被削減嗎?

  • Bary G. Bailey - EVP and CFO

    Bary G. Bailey - EVP and CFO

  • With respect to the royalties, what we have said for our analysis, we look at specialty pharma excluding the royalties and the R&D operation. We have done that going back to when Ribapharm was a separate entity from the current company and we have continued to believe that the royalties will fund, will be adequate to fund our R&D effort. Certainly if you took royalties away, took them down to zero, we would not want to stop our R&D efforts and that would obviously have a bottom-line impact to the total company as you have outlined.

    就權利金而言,針對我們的分析,我們看的是專科製藥業務,不包含權利金與研發營運。我們從 Ribapharm 尚為獨立於現今公司之前就一直這麼做,並且我們持續相信權利金將會、也足以資助我們的研發投入。當然,如果你把權利金拿掉、把它降到零,我們也不會想停止研發工作,而這顯然會如你所概述的那樣,對整體公司的最終盈餘造成影響。

  • Dave Groober - Analyst

    Dave Groober - Analyst

  • Great. Thank you.

    很好。謝謝。

  • Operator

    Operator

  • Andrew Sidoti from Wm. Smith & Co.

    Wm.Smith & Co. 的 Andrew Sidoti。

  • Andrew Sidoti - Analyst

    Andrew Sidoti - Analyst

  • Good morning gentlemen. Just a couple of questions. On the royalty revenue, again what is the split between domestic and international?

    各位先生早安。我有幾個問題。關於權利金收入,再請問一下,美國國內與國際之間的拆分比例是多少?

  • Unidentified Company Representative

    Unidentified Company Representative

  • About three-quarters of the royalty revenues in the fourth quarter came from -- out of the U.S.

    第四季約有四分之三的權利金收入來自——美國以外。

  • Andrew Sidoti - Analyst

    Andrew Sidoti - Analyst

  • How long are the patent protections on that royalty stream?

    那條權利金收入流的專利保護期有多長?

  • Unidentified Company Representative

    Unidentified Company Representative

  • Actually we rely on data exclusivity, predominately in Europe, and that takes us through 2008, and then the rest of the world is 2009 -- I'm sorry, I'm getting the two flipped around. On the rest of the world, it's around 2010 or is it --?

    其實我們主要依賴資料專屬權(data exclusivity),主要在歐洲,這可讓我們延續到 2008 年;然後世界其他地區是 2009 年——抱歉,我把兩個搞反了。至於世界其他地區,大約到 2010 年,還是——?

  • Unidentified Company Representative

    Unidentified Company Representative

  • That is correct.

    沒錯。

  • Unidentified Company Representative

    Unidentified Company Representative

  • With focus on the euro.

    重點在歐元區。

  • Andrew Sidoti - Analyst

    Andrew Sidoti - Analyst

  • Was there year-over-year growth in that component, international component, of the royalty revenues?

    權利金收入中的國際部分,年對年是否有成長?

  • Unidentified Company Representative

    Unidentified Company Representative

  • It has been fairly stable from a sale standpoint. There has been some impact from Roche entering. It obviously has not impacted the sales from that standpoint, but our royalties with Roche are lower than the Schering royalties in those markets. So that would have impacted our royalties to some degree.

    從銷售角度來看一直相當穩定。羅氏(Roche)進入後確實帶來一些影響。顯然就銷售而言並未造成影響,但在那些市場中,我們與羅氏的權利金率低於與 Schering 的權利金率。因此這在某種程度上影響了我們的權利金收入。

  • Unidentified Company Representative

    Unidentified Company Representative

  • I will say that if you look at the worldwide Midas (ph) data from IMS, you will see a year on year growth in most of the rest of the world markets by significant margin.

    我會說,如果你看 IMS 的全球 Midas(音)資料,你會看到世界其他多數市場年對年都有顯著成長。

  • Andrew Sidoti - Analyst

    Andrew Sidoti - Analyst

  • Last question was just on the acquisition front, what your criteria is and I know you can't comment on specifics, but I just wanted to know how, get a feel for how robust the acquisition pipeline is?

    最後一個問題是關於併購,你們的評估標準是什麼?我知道你們不能評論具體個案,但我想了解一下併購案源(pipeline)有多強勁?

  • Unidentified Company Representative

    Unidentified Company Representative

  • We're certainly continuing to look at and have looked at a lot of opportunities and we continue to focus and expect to provide some -- to be successful and to provide some information when we are. The way that we're looking at them I would just like to ask Bary to comment on that.

    我們當然持續在看、也已經看過很多機會;我們仍然聚焦,並且期望能——在成功時對外提供一些資訊。至於我們如何評估,我想請 Bary 來補充說明。

  • Bary G. Bailey - EVP and CFO

    Bary G. Bailey - EVP and CFO

  • We have said in the past, we don't specifically comment on hurdle rates or anything like that, other than to say that if you look at the acquisition we did of the buyback of Ribapharm, that should give you some indication of the hurdle rates. They obviously vary based on what we perceive to be the relative risk of the products or businesses that we had acquired. We are focused on our three therapeutic areas, and as evidenced by Wes heading up that business development area, we also have an emphasis on the U.S. opportunity, not ignoring international but an emphasis on the U.S. opportunity.

    我們過去說過,我們不會特別評論門檻報酬率(hurdle rates)或諸如此類的細節;但我可以說,如果你看我們對 Ribapharm 的回購式收購,那應該能讓你對門檻報酬率有些概念。這些門檻顯然會因我們對所收購產品或業務的相對風險認知而有所不同。我們聚焦於三個治療領域;而且如同 Wes 領導該業務開發領域所顯示的,我們也強調美國市場機會——並非忽視國際市場,但會更著重美國機會。

  • Andrew Sidoti - Analyst

    Andrew Sidoti - Analyst

  • Thank you very much.

    非常感謝。

  • Unidentified Company Representative

    Unidentified Company Representative

  • I just wanted to highlight, we are evaluating approximately 25 deals currently.

    我想補充強調一下,我們目前大約正在評估 25 個交易案。

  • Andrew Sidoti - Analyst

    Andrew Sidoti - Analyst

  • Okay. Thank you.

    好的。謝謝。

  • Operator

    Operator

  • Franz Tudor with Variant Research.

    Variant Research 的 Franz Tudor。

  • Franz Tudor - Analyst

    Franz Tudor - Analyst

  • A couple of quick questions. First on the operating margins of the base business. I know you explained why the margins fell in Europe but can you also talk about Asia? Sequentially we went from 14.5 percent down to 11, U.S. operating margins went from 43.75 back down to 42. What is going on with those trends?

    幾個快速問題。首先是核心業務的營業利益率。我知道你解釋了歐洲利益率下滑的原因,但也能談談亞洲嗎?按季來看,我們從 14.5% 降到 11%;美國的營業利益率從 43.75% 回落到 42%。這些趨勢是怎麼回事?

  • Unidentified Company Representative

    Unidentified Company Representative

  • Thanks for the question. I think it is tough to parcel out all of the different regions and look at them specifically. There are a lot of moving parts. Just as we're accelerating our overall manufacturing plan and strategy, there is a lot of activity going on to establish the dossier, that as I mentioned, we got a lot of investment going on around the world, getting the activities in place ready to relocate products so we can remove the excess capacity. Also, as Bary indicated, there has been some accelerated depreciation that has hit a number of parts of our operation. So, I think it is very difficult to take a particular quarter and look at it. If you look at the overall activity, and the trends, you will see that there has been some reduction, there has been some investment and will continue to be in this year to lead to some significant improvement in 2005 and after, as Rob had indicated.

    謝謝你的問題。我認為要把所有不同地區拆開來逐一看其實很難。有很多變動因素。正如我們正在加速整體製造計畫與策略一樣,為了建立我提到的檔案(dossier),有大量工作正在進行;如我所說,我們在全球各地有不少投資,將相關活動就位,為產品遷移做準備,以便移除過剩產能。另外,如 Bary 所指出的,我們營運的多個部分也受到一些加速折舊的影響。因此,我認為很難只看某一個季度就下結論。如果你看整體活動與趨勢,你會看到有一些下降、有一些投資,而且今年仍會持續,從而在 2005 年及之後帶來顯著改善,如 Rob 所提到的。

  • Bary G. Bailey - EVP and CFO

    Bary G. Bailey - EVP and CFO

  • Relative to, for example North America, our gross margins actually marginally improved between the third and fourth quarters. The sales, there is a sales variation. We don't see that is any indication of a trend. It is just the variabilities between quarters. As far as operating margins and I think it reflects the fact that we're willing to invest in sales on a prospective basis and as I indicated in my comments, we are expecting to continue to do that into the first and second quarters, but see that as that goes through the year that we will see those benefits ongoing for sales. We see a return on those investments in sales (indiscernible).

    相較之下,例如北美,我們的毛利率在第三季到第四季之間其實小幅改善。銷售方面存在一些波動。我們不認為那代表任何趨勢。那只是季度之間的變動。至於營業利益率,我認為這反映出我們願意以前瞻性的角度投資銷售;如我在評論中所說,我們預期在第一季與第二季仍會持續這麼做,但也認為隨著年度推進,我們將持續看到這些投入對銷售帶來的效益。我們看到這些銷售投資的回報(聽不清)。

  • Franz Tudor - Analyst

    Franz Tudor - Analyst

  • On Viramidine, is there the intent to possibly take an interim look at the data once you have enrolled say 500, 700 patients, something of that nature? But also if you could sort of walk us through the timeline, what you're expecting in terms of filing for Viramidine?

    關於 Viramidine,是否有意在例如收案 500、700 名病患後,對資料做一次期中檢視之類的?另外,能否請你帶我們走一遍時程,你們對 Viramidine 申報(filing)的預期是什麼?

  • Dr. Kim D. Lamon - President R&D and Chief Scientific Officer

    Dr. Kim D. Lamon - President R&D and Chief Scientific Officer

  • Regarding interim analyses, both of the pivotal studies do have incorporated in them an interim analysis. Regarding filing, we do not provide guidance on that but let me walk you through a couple of facts. On the trials of this size, 900 to 1,000 patients, have historically taken 12 months or more to enroll. The treatment herein for (indiscernible) patients at 18 months, so it is not unreasonable to think that these studies could take two or three years.

    關於期中分析,兩項關鍵性試驗都已納入期中分析設計。至於申報時點,我們不提供相關指引,但我可以帶你看幾個事實。以這種規模的試驗(900 到 1,000 名病患),歷來收案通常需要 12 個月或更久。此處(聽不清)病患的治療期為 18 個月,因此認為這些研究可能需要兩到三年並不不合理。

  • Franz Tudor - Analyst

    Franz Tudor - Analyst

  • Okay. At what point is the interim analysis potentially going to take place?

    好的。期中分析可能會在什麼時間點進行?

  • Dr. Kim D. Lamon - President R&D and Chief Scientific Officer

    Dr. Kim D. Lamon - President R&D and Chief Scientific Officer

  • It would be when the patients have completed, have gotten -- half of the patients have gotten through their treatment period, whether it be 24 weeks plus a follow up of 48 weeks (indiscernible) follow-up.

    會在病患完成治療時點,也就是——當有一半的病患走完其治療期時;不論是 24 週加上 48 週追蹤(聽不清)的追蹤期。

  • Franz Tudor - Analyst

    Franz Tudor - Analyst

  • Last question. On Efudex, Tera (ph) has already received generic approval for topical solution. Have you heard anything through the channel in terms of their getting the actual cream approval?

    最後一個問題。關於 Efudex,Tera(音)已經取得外用溶液的學名藥核准。你們是否從通路端聽到任何消息,關於他們是否會取得實際的乳膏(cream)核准?

  • Unidentified Company Representative

    Unidentified Company Representative

  • We have no information on any ANDAs that are submitted. We don't have any evidence or knowledge of any creams for them or any other company, but we again would not have visibility of that Franz, but the solution is less than 5 percent of our business.

    我們沒有任何關於已提交 ANDA 的資訊。我們也沒有任何證據或所知,顯示他們或其他公司有任何乳膏產品;但 Franz,我們同樣不會掌握那方面的能見度。不過溶液產品占我們業務不到 5%。

  • Operator

    Operator

  • Matt Tepalis (ph) from Quaker Capital Management.

    來自 Quaker Capital Management 的 Matt Tepalis(音)。

  • Matt Tepalis - Analyst

    Matt Tepalis - Analyst

  • Two questions. One, as it relates to foreign royalties, two questions related to that. One, are those dollar-denominated, and also do they reflect Schering's excess inventory positions? I guess my question is do they really reflect accurate run rate sales?

    兩個問題。第一個,關於海外權利金,有兩個相關問題。其一,這些是以美元計價嗎?另外,它們是否反映了 Schering 的過剩庫存部位?我想問的是,它們是否真的反映了準確的經常性銷售水準(run rate sales)?

  • Unidentified Company Representative

    Unidentified Company Representative

  • Let me answer the second question and Bary can answer the first. The second question is the wholesale inventory issue is a U.S. only issue, but doesn't affect the global activities.

    我先回答第二個問題,第一個問題 Bary 可以回答。第二個問題是,批發端庫存的議題只發生在美國,但不影響全球業務活動。

  • Bary G. Bailey - EVP and CFO

    Bary G. Bailey - EVP and CFO

  • As far as the way the royalties are calculated they are obviously sold in local currency, and then Schering translates those and pays us in U.S. dollars.

    至於權利金的計算方式,顯然是以當地貨幣銷售,然後 Schering 會把那些金額換算後以美元支付給我們。

  • Matt Tepalis - Analyst

    Matt Tepalis - Analyst

  • So they are ultimately going to be subject then to the fluctuation of the U.S. dollar indirectly, I guess?

    所以最終它們就會間接受到美元匯率波動的影響,對吧?

  • Bary G. Bailey - EVP and CFO

    Bary G. Bailey - EVP and CFO

  • Yes.

    是的。

  • Matt Tepalis - Analyst

    Matt Tepalis - Analyst

  • Secondly, you did speak a little bit about the recently consummated acquisition, but could you talk a little bit more about it, what really drove it since I guess it's earnings neutral in '04 and obviously not a great deal of size? What were you most interested in? What prompted the deal?

    第二,你確實稍微談到最近完成的收購,但你能再多談一些嗎?是什麼真正驅動這筆交易?因為我想它在 2004 年對盈餘是中性的,而且顯然規模也不大。你們最感興趣的是什麼?是什麼促成了這筆交易?

  • Unidentified Company Representative

    Unidentified Company Representative

  • We are interested in three therapeutic areas which we have discussed. Central nervous system is one of those. This was a nice little opportunity to add a small neurology salesforce, add an approvable drug for Parkinson's disease and in-line drug for Parkinson's. So, a nice opportunity to add and strengthen a platform in the business and to add about $20 million of sales. And again the pipeline drug gave us an opportunity where the product is potentially close to marketplace.

    我們對三個治療領域感興趣,之前也討論過。中樞神經系統是其中之一。這是一個很好的小機會:增加一支小型神經科銷售團隊,加入一個可望獲准的帕金森氏症藥物,以及一個在研的帕金森氏症藥物。因此,這是強化我們業務平台的好機會,並可增加約 2,000 萬美元的銷售額。同樣地,研發管線藥物也讓我們有機會,因為該產品可能接近上市。

  • Matt Tepalis - Analyst

    Matt Tepalis - Analyst

  • In terms of the approvable drug, could you give any sense of what you view the opportunity for this drug in terms of -- roughly sizing it?

    就那個可望獲准的藥物而言,你能否大致說明一下你們認為它的機會有多大——大概的規模?

  • Unidentified Company Representative

    Unidentified Company Representative

  • I'm going to ask Wes to just make a comment on that.

    我請 Wes 就此做個簡短說明。

  • Wes Wheeler - President, North America and Global Marketing and Business Development

    Wes Wheeler - President, North America and Global Marketing and Business Development

  • Zelapar is a new formulation of Selegilene which is already a well-established compound in the Parkinson's disease market. We're not going to give guidance on future forecasts of that product, but I think if you look at the IMS data for that disease area you will see that Selegilene has a large opportunity in the marketplace. It is a very, very elegant formulation of that product.

    Zelapar 是 Selegilene 的一種新劑型,而 Selegilene 在帕金森氏症市場已是相當成熟、廣為使用的化合物。我們不會對該產品未來的預測提供指引,但我想如果你查看 IMS 在該疾病領域的數據,你會看到 Selegilene 在市場上有很大的機會。這是一個非常、非常精緻的劑型。

  • Matt Tepalis - Analyst

    Matt Tepalis - Analyst

  • Could you just -- roughly what Selegilene's sales are?

    你能否——大概說一下 Selegilene 的銷售額是多少?

  • Unidentified Company Representative

    Unidentified Company Representative

  • Worldwide sales of Selegiline, I don't have that data at my fingertips. U.S. sales of Selegiline, really it is both the combination of generic Eldepryl and (indiscernible). Let's get back to you on that.

    Selegiline 的全球銷售額,我手邊沒有那個數據。Selegiline 在美國的銷售額,實際上包含學名藥 Eldepryl 與(聽不清)。我們之後再回覆你。

  • Unidentified Company Representative

    Unidentified Company Representative

  • We'll look that up and give you a comment in a minute.

    我們會查一下,稍後給你一個說明。

  • Operator

    Operator

  • Neil Shaw (ph) from Frontier Capital.

    Frontier Capital 的 Neil Shaw(音)。

  • Neil Shaw - Analyst

    Neil Shaw - Analyst

  • Good morning. I was calling you on the -- two questions. On the base business, forgetting about Viramidine looking out a few years from now, what do you think the -- and I'm also stripping out sort of royalties. What do you think the operating margins should be and can be? So sort of realistic and maybe even be more optimistic looking out a few years and taking into account all that you are doing with regard to the manufacturing and restructuring and etc.? That is the first question?

    早安。我打電話來有——兩個問題。關於基礎業務,先不談 Viramidine,往後看幾年,你認為——我也把權利金先剔除——你認為營業利益率應該、也能達到多少?也就是說,較務實的情境,甚至更樂觀一點,並把你們在製造、重整等方面所做的一切都考慮進去。這是第一個問題?

  • Unidentified Company Representative

    Unidentified Company Representative

  • We have considered that in our information we have provided already to the marketplace on the different margins, the cost of goods sold, and the selling expense. So you can look at what we have already communicated. This will be a high gross margin product because it's an oral dosage form and the majority of the business will come out of North America and Europe.

    我們已在先前提供給市場的資訊中,針對不同的利潤率、銷貨成本以及銷售費用做過考量。所以你可以參考我們已經對外溝通的內容。這將是一個高毛利產品,因為它是口服劑型,而且大部分業務將來自北美與歐洲。

  • Neil Shaw - Analyst

    Neil Shaw - Analyst

  • I'm talking about X-Viramidine and ex the royalties, just sort of the base business you've got today?

    我指的是不含 X-Viramidine、也不含權利金,就是你們今天現有的基礎業務?

  • Unidentified Company Representative

    Unidentified Company Representative

  • We will try to give you a sense of that, but just a little bit tongue and cheek. The (indiscernible) answer your question is a difficult thing for us to do. We're not very focused on talking about things excluding Viramidine because that is where we are obviously placing a lot of our investment in this company and a lot of activity in every division of the company to prepare for manufacturing and commercialization as well as accelerating the R&D activities. So we will get back to you in just a couple of minutes here on your question, but just for the record your predicate is not really one we accept.

    我們會試著給你一些概念,但稍微開個玩笑說。要(聽不清)回答你的問題對我們來說有點困難。我們並不太專注於在排除 Viramidine 的情況下談論事情,因為顯然那是我們在這家公司投入大量資金的方向,而且公司各部門也有大量活動在為製造與商業化做準備,同時加速研發活動。所以我們會在接下來幾分鐘內再回到你的問題,但先說明,你的前提並不是我們真正接受的前提。

  • Unidentified Company Representative

    Unidentified Company Representative

  • I can just say that the cost of goods sold information that we have provided is not dependant upon Viramidine.

    我只能說,我們所提供的銷貨成本資訊並不依賴 Viramidine。

  • Neil Shaw - Analyst

    Neil Shaw - Analyst

  • Right. And that is an accumulative number, that 150 to 200?

    了解。而且那是累計數字,也就是 1.5 億到 2 億?

  • Unidentified Company Representative

    Unidentified Company Representative

  • Yes.

    是的。

  • Neil Shaw - Analyst

    Neil Shaw - Analyst

  • Then the other thing is Japan and -- Schering and Roche have not entered Japan right?

    另外,日本那邊——Schering 和 Roche 還沒有進入日本,對吧?

  • Unidentified Company Representative

    Unidentified Company Representative

  • Schering is in the marketplace, and Roche is going to enter.

    Schering 已經在市場上了,而 Roche 將會進入。

  • Neil Shaw - Analyst

    Neil Shaw - Analyst

  • Alright. Thank you.

    好。謝謝。

  • Operator

    Operator

  • Kathy Reece (ph) with CHR Research.

    CHR Research 的 Kathy Reece(音)。

  • Kathy Reece - Analyst

    Kathy Reece - Analyst

  • Good morning. Going back to Viramidine, with the generics expected to be on the market for possibly four years by 2008, what are you anticipating will be the actual market size opportunity for Viramidine by 2008? Another just kind of a housekeeping question, I think you mentioned earlier that your R&D would be higher in the first part of 2004 and with a Phase III starting, another Phase III starting in the second half of 2004, I was just curious how that was happening? (indiscernible), that would be great.

    早安。回到 Viramidine,如果預期到 2008 年學名藥可能已在市場上達到四年之久,你們預期到 2008 年 Viramidine 實際可掌握的市場規模機會會是多少?另外一個比較行政性的問題,我想你先前提到 2004 年前半段研發費用會較高,而且第三期試驗啟動、2004 年下半年還會再啟動另一個第三期試驗,我只是好奇這是怎麼安排的?(聽不清),如果能說明就太好了。

  • Unidentified Company Representative

    Unidentified Company Representative

  • Firstly on the second question, we're going to have a Phase II study starting, not another Phase III study unless you mean Pfizer (ph) II. So we have Pfizer II starting in the mid of the year and all of the guidance or information that we have given you included that information. So we have provided information that we believe our expenses for the year is going to the $85 to $95 million. That includes all of the investments in R&D that we have in our plan.

    先回答第二個問題,我們將啟動的是一項第二期研究,不是另一項第三期研究,除非你指的是 Pfizer(音)II。所以我們會在年中啟動 Pfizer II,而我們給你的所有指引或資訊都已包含這點。因此我們提供的資訊是,我們認為今年的費用將在 8,500 萬到 9,500 萬美元之間。這包含我們計畫中所有研發投資。

  • Kathy Reece - Analyst

    Kathy Reece - Analyst

  • So broken down during the year though, a lot of that will still be during the first half?

    但如果按年度拆分的話,其中很大一部分仍會發生在上半年嗎?

  • Unidentified Company Representative

    Unidentified Company Representative

  • It is more likely to be -- it is going to ramp up. As you know clinical programs take time to get started, so we're just -- we began as you well know in late November, early December, in the first part of the study and the second part will begin in the midpart of the year. So as we ramp up the expenditures will also start ramping up.

    更可能是——會逐步拉升。如你所知,臨床計畫需要時間啟動,所以我們——如你很清楚——在 11 月底、12 月初開始了研究的第一部分,而第二部分將在年中開始。因此,隨著我們逐步推進,支出也會開始逐步增加。

  • Robert W. O'Leary - Chairman and CEO

    Robert W. O'Leary - Chairman and CEO

  • Let me just interject. In your original question and the follow-up, I'm detecting that you thought you heard us say that the R&D costs was front-end loaded. The only thing we said like that was in reference to the manufacturing costs. The R&D costs are not primarily in the front in the first half, they are -- on an annual basis they are across the year and they will if anything be moving upwards as the number of studies involved are engaged.

    我補充一下。從你原本的問題和追問來看,我感覺你以為你聽到我們說研發成本是前期集中(front-end loaded)。我們唯一類似的說法是針對製造成本。研發成本並不是主要集中在上半年;以全年來看是分布在整年,而且如果有什麼趨勢的話,隨著投入的研究數量增加,研發成本反而會往上走。

  • Dr. Kim D. Lamon - President R&D and Chief Scientific Officer

    Dr. Kim D. Lamon - President R&D and Chief Scientific Officer

  • I just want to make one point of clarification Kathy regarding the studies. The Phase II program is still ongoing. We used the twelve week data to make a decision to go to Phase III. So that study with about 180 patients is still ongoing and the data from that (technical difficulty) of that study will be presented in mid-April at an EASL meeting. We do have two Phase III's in-process of Viramidine. One of those has started the end of last year and is in the enrollment phase, and we're going to kick off the second Phase III study, same size, about 1,000 patients in 80 to 100 sites. That will kick off in the back half of the year.

    Kathy,關於這些研究我只想澄清一點。第二期(Phase II)計畫仍在進行中。我們使用了12週的數據來做出進入第三期(Phase III)的決定。因此,那項約180名病患的研究仍在進行中,而該研究的數據(技術問題)將於4月中旬在EASL會議上發表。我們目前有兩項Viramidine的第三期試驗正在進行。其中一項於去年年底啟動,正處於收案階段;我們也將啟動第二項同等規模的第三期研究,約1,000名病患、80到100個試驗中心。該研究將在今年下半年啟動。

  • Kathy Reece - Analyst

    Kathy Reece - Analyst

  • So then 2005 is going to be similar to 2004 expected (indiscernible)?

    那麼2005年將會與2004年類似,符合預期(聽不清楚)嗎?

  • Dr. Kim D. Lamon - President R&D and Chief Scientific Officer

    Dr. Kim D. Lamon - President R&D and Chief Scientific Officer

  • Everything really depends on enrollment in the study. It is very hard to answer because of the enrollment period. Certainly those studies, since they carry over two to three years, the expense will follow.

    一切其實都取決於研究的收案情況。由於收案期的關係,這很難回答。當然,這些研究因為會延續兩到三年,費用也會隨之發生。

  • Unidentified Company Representative

    Unidentified Company Representative

  • Let me say it another way, Kathy, and then we are going to have to move on to the final two questions. One, we have given you a specific number for R&D expense for this year and we don't expect it to go down in the following year.

    Kathy,我換個方式說,然後我們必須進入最後兩個問題。第一,我們已經給了你今年研發費用的具體數字,而且我們不預期明年會下降。

  • Kathy Reece - Analyst

    Kathy Reece - Analyst

  • Thank you.

    謝謝。

  • Unidentified Company Representative

    Unidentified Company Representative

  • I just want to make a comment about your first question which we didn't mention, and that is your question about the value of Viramidine in the marketplace with generics. The value proposition for Viramidine if the clinical studies prove what the early data shows, will be a significant reduction in the incidence of anemia which is a very difficult issue and the reason for most patients to drop out of therapy. So if the proposition proves true, there will be an extra value in Viramidine and we will have a huge impact on the marketplace, as well as, there are people that are suffering from anemia that receive about a $10,000 to $15,000 treatment. So there is a huge opportunity there.

    我想就你第一個問題補充一點,我們剛才沒有提到的,也就是你問到在有學名藥的情況下,Viramidine在市場上的價值。如果臨床研究證實早期數據所顯示的結果,Viramidine的價值主張將是能顯著降低貧血的發生率;貧血是一個非常棘手的問題,也是多數病患中止治療的原因。因此,如果這個主張被證實,Viramidine將具備額外價值,並會對市場產生巨大影響;此外,還有一些因貧血而需要接受約10,000到15,000美元治療的患者。所以那裡存在很大的機會。

  • Kathy Reece - Analyst

    Kathy Reece - Analyst

  • Okay. Thanks.

    好的。謝謝。

  • Operator

    Operator

  • Tony Fiorini (ph) from Sands Point Partners.

    Sands Point Partners的Tony Fiorini(音)。

  • Tony Fiorini - Analyst

    Tony Fiorini - Analyst

  • I had a question. You mentioned that headcount was down 42 percent year-over-year, yet I see SG&A down only 11 percent year-over-year in the quarter. I'm just trying to understand when we'll actually see some leverage on the SG&A line from these restructurings?

    我有個問題。你提到人員編制年比年下降了42%,但我看到本季SG&A年比年只下降了11%。我只是想了解,我們何時才能真正從這些重整措施中,在SG&A這一項看到一些槓桿效應?

  • Unidentified Company Representative

    Unidentified Company Representative

  • Let me first, if you'll forgive me, reclarify what I said. I didn't say headcount was down 42 percent. I said it was down to 42 percent of what it was, so it's actually down 58 percent. But remember, most of that is as a result of our divestiture program, some of it is from headquarter reductions as well and a lot of that is in manufacturing in Russia, etc. Tim perhaps will answer the rest of the question.

    首先,如果你不介意,我先澄清我剛才說的話。我不是說人員編制下降了42%。我是說降到原來的42%,所以實際上是下降了58%。但請記得,其中大部分是我們資產剝離計畫的結果,部分也來自總部縮編,還有很多是在俄羅斯等地的製造部門。Tim或許會回答其餘的問題。

  • Timothy C. Tyson - President and COO

    Timothy C. Tyson - President and COO

  • There have been some significant impacts already to SG&A. SG&A is down significantly. As Rob indicated, a lot of the headcount reduction were in our discontinued operations, and so have been taken out of our financials. As you look at information, you will see that there has been some impact to SG&A already, and the manufacturing impacts will mostly accrue to cost of goods sold.

    SG&A其實已經受到一些顯著影響。SG&A已大幅下降。如Rob所指出,許多的人員縮減發生在我們已終止的營運中,因此已從我們的財務報表中剔除。當你查看相關資訊時,你會看到SG&A已經有一些影響,而製造端的影響多半會反映在銷貨成本上。

  • Tony Fiorini - Analyst

    Tony Fiorini - Analyst

  • Okay. Thank you.

    好的。謝謝。

  • Operator

    Operator

  • Alan Sapolsky (ph) from Apothecary Capital.

    Apothecary Capital的Alan Sapolsky(音)。

  • Alan Sapolsky - Analyst

    Alan Sapolsky - Analyst

  • My first question has been answered, but just as a quick follow-up. Are you going to begin disclosing the quarterly sales numbers on an ongoing basis for product sales -- for the specific products that you have been getting on an annual basis?

    我的第一個問題已經被回答了,但我想快速追問一下。你們是否會開始以持續方式揭露各產品的季度銷售數字——也就是你們過去按年度提供的那些特定產品的銷售數字?

  • Unidentified Company Representative

    Unidentified Company Representative

  • We will be providing information on the products that we have discussed and that we disclosed during this release. So you have information on our global products and our top ten products, if that is what you are talking about.

    我們會提供我們已討論過、且在本次公告中揭露的產品資訊。所以你會有我們全球產品以及前十大產品的資訊,如果你指的是這些的話。

  • Alan Sapolsky - Analyst

    Alan Sapolsky - Analyst

  • But will you begin to disclose those on a quarterly basis?

    但你們會開始按季度揭露那些資訊嗎?

  • Unidentified Company Representative

    Unidentified Company Representative

  • We haven't made a decision on that at this point.

    目前我們尚未就此做出決定。

  • Alan Sapolsky - Analyst

    Alan Sapolsky - Analyst

  • Okay. Thank you.

    好的。謝謝。

  • Unidentified Company Representative

    Unidentified Company Representative

  • There was one question, who is it? Neil Shaw had asked a question relative to the operating margins. We have historically indicated that we expect to see that over 20 percent and that is reflected from our 2008 margin indication. If you just add up our percentages from the presentations we have done, the amount would range between 21 percent and 35 percent excluding amortization.

    還有一個問題,是誰?Neil Shaw曾就營業利益率提出一個問題。我們過去一向表示,我們預期會看到超過20%,而這也反映在我們對2008年毛利率(margin)的指引中。如果你把我們在簡報中提出的百分比加總,排除攤銷後,該數字範圍大約在21%到35%之間。

  • Unidentified Company Representative

    Unidentified Company Representative

  • I want to thank everyone for your questions and your patience today. Just in very quick summary, as we finished this really first significant transformation year, I would tell you that most of all the restructuring really is done. Clearly we are focused on our specialty pharmaceuticals business and are free of many of the distractions of the past.

    感謝各位今天的提問與耐心。非常簡短地總結一下,當我們完成這第一個重要的轉型年度時,我會告訴你們,大部分的重整其實都已完成。很明顯地,我們專注於專科製藥業務,也已擺脫過去許多分散注意力的因素。

  • We are on schedule or ahead of schedule in our manufacturing rationalization in R&D investments, and in fact while we continue to work hard on the specialty pharmaceutical business and have to deal with the uncertainty of the generic entry, we really are very, very comfortable with the midterm and longer term view of the platform that has been created here and what we can do with this company in the years ahead. Thank you all very much for your participation today. We look forward to talking to you again.

    我們在製造合理化與研發投資方面按計畫進行,甚至超前進度;事實上,雖然我們持續努力推動專科製藥業務,並必須面對學名藥進入的不確定性,但對於已建立的平台之中期與長期展望,以及未來幾年我們能用這家公司做到的事情,我們感到非常、非常有信心。非常感謝各位今天的參與。我們期待再次與各位交流。

  • Operator

    Operator

  • This concludes today's call. Thank you for your participation. At this time, you may now disconnect from the conference.

    今天的電話會議到此結束。感謝各位的參與。此時您可以中斷與會議的連線。